Anti-Human CD137 (4-1BB) (Urelumab) – Fc Muted™ - 500 µg

All|Recombinant Antibodies>Biosimilar Recombinant Antibodies|Primary Monoclonal Antibodies

2 - 8°C Wet Ice

CD137, also known as 4-1BB or TNFRSF9, is a member of the tumor necrosis factorreceptor (TNFR) superfamily. It is a type I transmembrane protein expressed on the surfaceof activated T cells, natural killer (NK) cells, dendritic cells, and other immune cells. CD137functions as a co-stimulatory molecule, enhancing T cell proliferation, survival, and cytokineproduction upon binding to its ligand, CD137L. This interaction plays a crucial role inimmune responses, making CD137 an attractive target for cancer immunotherapy1-3. BMS-66513, also known as urelumab, is a humanized IgG4 monoclonal antibody that acts asan agonist for CD137. By binding to CD137, urelumab enhances the activation andproliferation of T-cells and NK cells, leading to increased antitumor activity. It has shownpotential in potentiating tumor cell killing and enhancing the cytotoxicity of other therapeuticantibodies like rituximab. Urelumab is being investigated for its efficacy in treating varioussolid tumors and hematological malignancies4-6.

≥ 5.0 mg/ml

CD137 is expressed on the surface of activated T cells, NK cells, dendritic cells, and other immune cells.